540788 ASPIRA

Aspira Pathlab & Diagnostics Share Price

₹77.74 -1.58 (-1.99%)

22 Jan, 2025 17:04

SIP TrendupStart SIP in ASPIRA

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month + 25.19%
  • Over 3 Month + 59.5%
  • Over 6 Month + 150.77%
  • Over 1 Year + 126.71%
SIP Lightning

Smart Investing Starts Here Start SIP with Aspira Pathlab & Diagnostics for Steady Growth!

Invest Now

Aspira Pathlab & Diagnostics Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Aspira Pathlab & Diagnostics Financials

Aspira Pathlab & Diagnostics Technicals

EMA & SMA

Current Price
₹77.74
-1.58 (-1.99%)
pointer
  • stock-down_img
  • Bearish Moving Average 2
  • stock-up_img
  • Bullish Moving Average 14
  • 20 Day
  • ₹72.58
  • 50 Day
  • ₹66.59
  • 100 Day
  • ₹58.47
  • 200 Day
  • ₹49.55

Resistance and Support

79.32 Pivot Speed
  • R3 79.32
  • R2 79.32
  • R1 79.32
  • S1 79.32
  • S2 79.32
  • S3 79.32

What's your outlook on Aspira Pathlab & Diagnostics?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Aspira Pathlab & Diag has an operating revenue of Rs. 14.63 Cr. on a trailing 12-month basis. An annual revenue de-growth of -8% needs improvement, Pre-tax margin of -20% needs improvement, ROE of -51% is poor and needs improvement. The company has a reasonable debt to equity of 21%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 14% and 80% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around -0% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 63 which is a FAIR score but needs to improve its earnings, a RS Rating of 94 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 62 indicates it belongs to a poor industry group of Medical-Services and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Aspira Pathlab & Diagnostics Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-12 Quarterly Results
2024-08-13 Quarterly Results
2024-05-28 Audited Results
2024-02-13 Quarterly Results
2024-02-10 Quarterly Results

Aspira Pathlab & Diagnostics F&O

Aspira Pathlab & Diagnostics Shareholding Pattern

18.55%
60.28%
21.17%

About Aspira Pathlab & Diagnostics

  • NSE Symbol
  • ASPIRA
  • BSE Symbol
  • 540788
  • Managing Director & CEO
  • Dr. Pankaj J Shah
  • ISIN
  • INE500C01017

Similar Stocks to Aspira Pathlab & Diagnostics

Aspira Pathlab & Diagnostics FAQs

Aspira Pathlab & Diagnostics share price is ₹77 As on 22 January, 2025 | 16:50

The Market Cap of Aspira Pathlab & Diagnostics is ₹80 Cr As on 22 January, 2025 | 16:50

The P/E ratio of Aspira Pathlab & Diagnostics is -295.3 As on 22 January, 2025 | 16:50

The PB ratio of Aspira Pathlab & Diagnostics is 15.3 As on 22 January, 2025 | 16:50

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23